CareLit · DOI-Nachweis · Pneumologie
Effect of baseline FVC on decline in lung function with nintedanib: results from the INPULSIS™ trials
DOI 10.1055/s-0035-1544867
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, Y Inoue, L Richeldi, HR Collard, S Stowasser, I Tschoepe, A Azuma
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Nintedanib, an intracellular inhibitor of tyrosine kinases, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate randomized, double-blind, placebo-controlled, 52-week Phase III trials that assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF. The primary endpoint was the annual rate of decline in forced vital…
Zitieren
Zitierempfehlung
U Costabel, Y Inoue, L Richeldi, HR Collard, S Stowasser, I Tschoepe, A Azuma (2015) Effect of baseline FVC on decline in lung function with nintedanib: results from the INPULSIS™ trials. Pneumologie (02). https://doi.org/10.1055/s-0035-1544867
Mit CareLit weiterarbeiten